SAB immunotherapy neutralizes Ebola in animal study
Sioux Falls-based SAB Biotherapeutics used its anti-Ebola immunotherapy to provide 100 percent protection against a lethal dose of the disease in a recent animal study.
Sioux Falls-based SAB Biotherapeutics used its anti-Ebola immunotherapy to provide 100 percent protection against a lethal dose of the disease in a recent animal study.